273 related articles for article (PubMed ID: 22046525)
1. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis.
Hashizume M; Mihara M
Arthritis; 2011; 2011():765624. PubMed ID: 22046525
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.
Mihara M; Ohsugi Y; Kishimoto T
Open Access Rheumatol; 2011; 3():19-29. PubMed ID: 27790001
[TBL] [Abstract][Full Text] [Related]
3. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
4. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts].
Seemayer CA; Distler O; Kuchen S; Müller-Ladner U; Michel BA; Neidhart M; Gay RE; Gay S
Z Rheumatol; 2001 Oct; 60(5):309-18. PubMed ID: 11759230
[TBL] [Abstract][Full Text] [Related]
6. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
7. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.
Srirangan S; Choy EH
Ther Adv Musculoskelet Dis; 2010 Oct; 2(5):247-56. PubMed ID: 22870451
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
[TBL] [Abstract][Full Text] [Related]
9. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Romas E; Gillespie MT; Martin TJ
Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.
Kwok SK; Cho ML; Park MK; Oh HJ; Park JS; Her YM; Lee SY; Youn J; Ju JH; Park KS; Kim SI; Kim HY; Park SH
Arthritis Rheum; 2012 Mar; 64(3):740-51. PubMed ID: 21968544
[TBL] [Abstract][Full Text] [Related]
11. NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis.
Liu H; Zhu Y; Gao Y; Qi D; Zhao L; Zhao L; Liu C; Tao T; Zhou C; Sun X; Guo F; Xiao J
Cell Death Dis; 2020 Feb; 11(2):129. PubMed ID: 32071294
[TBL] [Abstract][Full Text] [Related]
12. Bone destruction in arthritis.
Gravallese EM
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii84-6. PubMed ID: 12379632
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis.
Koenders MI; Kolls JK; Oppers-Walgreen B; van den Bersselaar L; Joosten LA; Schurr JR; Schwarzenberger P; van den Berg WB; Lubberts E
Arthritis Rheum; 2005 Oct; 52(10):3239-47. PubMed ID: 16200598
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.
Dickerson TJ; Suzuki E; Stanecki C; Shin HS; Qui H; Adamopoulos IE
J Autoimmun; 2012 Dec; 39(4):369-76. PubMed ID: 22867712
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
16. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling.
Miao CG; Yang YY; He X; Li XF; Huang C; Huang Y; Zhang L; Lv XW; Jin Y; Li J
Cell Signal; 2013 Oct; 25(10):2069-78. PubMed ID: 23602936
[TBL] [Abstract][Full Text] [Related]
17. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis.
Xin PL; Jie LF; Cheng Q; Bin DY; Dan CW
Front Pharmacol; 2021; 12():655114. PubMed ID: 34054534
[TBL] [Abstract][Full Text] [Related]
20. [IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis].
Murakami M; Nishimoto N
Clin Calcium; 2015 Dec; 25(12):1851-7. PubMed ID: 26608861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
